Purpose: To ascertain whether complex dynamic contrast enhanced (DCE) MRI tracer kinetic models are supported by data acquired in the clinic and to determine the consequences of limited contrast-to-noise. Methods: Generically representative in silico and clinical (cervical cancer) DCE-MRI data were examined. Bayesian model selection evaluated support for four compartmental DCE-MRI models: the Tofts model (TM), Extended Tofts model, Compartmental Tissue Uptake model (CTUM), and Two-Compartment Exchange model. Results: Complex DCE-MRI models were more sensitive to noise than simpler models with respect to both model selection and parameter estimation. Indeed, as contrast-to-noise decreased, complex DCE models became less probable and simpler models more probable. The less complex TM and CTUM were the optimal models for the DCE-MRI data acquired in the clinic. [In cervical tumors, K trans , F p , and PS increased after radiotherapy (P ¼ 0.004, 0.002, and 0.014, respectively)]. Conclusion: Caution is advised when considering application of complex DCE-MRI kinetic models to data acquired in the clinic. It follows that data-driven model selection is an important prerequisite to DCE-MRI analysis. Model selection is particularly important when high-order, multiparametric models are under consideration. (Parameters obtained from kinetic modeling of cervical cancer clinical DCE-MRI data showed significant changes at an early stage of radiotherapy.) Magn
INTRODUCTION
Dynamic contrast enhanced (DCE) MRI is being used increasingly in the assessment of cancer, both pre-and post-therapy (1) (2) (3) (4) (5) (6) (7) (8) (9) . Both semiquantitative (1-4) and quantitative analyses (4-9) of time-resolved DCE-MRI data are used to derive information about tumor microcirculation and microvasculature. Semiquantitative analyses, which derive measures directly from MR signal intensities, depend on MR hardware and the pulse sequences used to acquire the data, making it challenging to compare results between studies. In addition, the derived parameters, including signal-intensity plateau, contrast-enhancement ratio, and area under the curve, have no clear physiological meaning (4, 10) . By contrast, quantitative analysis using tracer kinetic models yields physiological parameters related to tissue perfusion and capillary permeability.
Many tracer kinetic models have been applied to describe the behavior of administered contrast agent in DCE-MRI experiments. The first generation of DCE-MRI models, including the widely used Tofts model (TM) (11) , were designed for tissues with negligible blood volume, and were used to characterize the permeability of the tissue vasculature. To account for intravascular signal contributions, the Extended Tofts Model (ETM) (12, 13) was introduced for highly perfused tissues, including tumors. Improvements in scanner hardware and software, which have led to higher-quality DCE-MRI data, have motivated the development of models with greater complexity (14, 15) that more fully describe tissue perfusion and capillary permeability. Such models are physiologically more accurate (fewer assumptions/constraints regarding tissue structure) compared with reduced, simpler models that make physiological assumptions or introduce constraints that may not be appropriate for the tissue of interest and will, thus, generate bias in kinetic parameter estimates. However, in practice, it remains unknown whether these more complex models are supported by a given clinical DCE-MRI dataset with specific data quality [e.g., time resolution, acquisition time window, and contrast-to-noise ratio (CNR)]. Thus, it is important to apply model selection, a data-driven process that balances the goodness of the fit and the stability of parameter estimation, to choose which kinetic model within a family of competing models best characterizes (is best supported by) the data.
The importance of selecting an appropriate DCE tracer kinetic model for measurement of tissue perfusion and capillary permeability has been examined in previous reports from other laboratories (16, 17) . Model selection algorithms, including Chi-square (18) , Akaike information criterion (AIC) (18) (19) (20) , F-test (21) (22) (23) , and the DurbinWatson statistic (18, 24) , have been applied to evaluate tracer kinetic models commonly used in DCE-MRI data analyses. However, very few of these studies have tested the stability of complex models as a function of data quality in the context of a pool of competing models. Luypaert et al (25) , and Murase (26) , investigated the effect of noise on the parameter estimation of individual DCE-MRI tracer kinetic models, but did not compare the accuracy and uncertainty of parameter estimation between models.
Bayesian probability theory (27) provides a rigorous statistical formalism for performing model-selection calculations. Advances in computational power and the development of Markov-chain Monte Carlo (MCMC) methods have greatly increased the applicability of Bayesian inference to a range of problems. Using a Bayesian approach, the modelselection problem is addressed by treating the model itself as a parameter, for which the posterior probability, given the data and prior information, is computed.
The goal of this study was to test four compartmental tracer kinetic models against generically representative DCE-MRI data. Both in silico DCE-MRI data, simulated based on each of the four models, and clinical DCE-MRI cervical cancer data acquired pretreatment and 2 to 3 weeks following the start of radiotherapy (RT), were used. Bayesian-based model selection and parameter estimation algorithms were applied to evaluate the noise tolerance to data analysis for each kinetic model and the dependence of the accuracy and uncertainty of parameter estimation on both model complexity and signal contrast-to-noise. Finally, applying model selection to clinical DCE-MRI cervical cancer data on a voxel-byvoxel basis, optimal models for the data were determined and then used to estimate physiological parameters, including perfusion metrics and vascular permeability.
METHODS

DCE-MRI Tracer Kinetic Models
Tracer kinetic modeling of vascular leakage and conservation of mass allow the tissue contrast-agent concentration (C t ) obtained following the administration of a contrast agent bolus to be written as:
where C p ðtÞ is the concentration of the contrast agent in the plasma of the capillary inlet of any region of interest (ROI), commonly approximated by a measured upstream arterial input function (AIF), and IðtÞ is the tissue impulseresponse function to the contrast agent input, which depends on the specific DCE-MRI tracer kinetic model. In this expression, "" denotes the convolution operation. Landis and colleagues (28) have pointed out that, in principle, "tracer kinetic" models are inappropriate for DCE-MRI data because C t is not directly measured. Rather, it is the tissue water 1 H relaxation enhancement caused by the agent that is monitored. Under some circumstances, the relaxation enhancement will be a nonlinear function of C t , requiring consideration of additional parameters not generally included in tracer kinetic models, e.g., the rate constant(s) governing water exchange across the relevant compartment boundaries. Such models are more complex than those considered herein. In practice, under conditions that approximate the MR-relaxation fast-exchange limit (29) , the relaxation enhancement reasonably approximates a linear function of C t , and tracer kinetic models are appropriate simplifications of a more complex system. Data described herein are consistent with this simplification. Four compartmental DCE tracer kinetic models were included in this model selection study: (i) the fourparameter (F p , v e , v p , and PS) Two-Compartment Exchange Model (2CXM), (ii) the three-parameter (F p , v p , and PS) Compartmental Tissue Uptake Model (CTUM); (iii) the three-parameter (K trans , v e , and v p ) ETM; and (iv) the two-parameter (K trans and v e ) Tofts Model (TM). In these models, F p is blood flow, v e is the extracellularextravascular volume fraction, v p is the plasma volume fraction, PS is the permeability-surface area product, and K trans is the forward volume transfer-rate constant. Figure 1 and Table 1 summarize the hierarchy and impulse response functions of these models. Further details about the relationships among these models are given in Sourbron and Buckley (16) . In addition to the DCE tracer kinetic models, a "no signal" model, in which the data are assumed to consist only of noise, was also included, by default, in the model-selection calculation.
Clinical DCE-MRI Data
De-identified clinical DCE-MRI cervical cancer data were acquired from patients enrolled in the EMBRACE study (16) . Under various physiological conditions, the general 2CXM, in which contrast agent is distributed into two separate compartments (vascular and extracellular-extravascular spaces), reduces to the simpler ETM, CTUM, and TM. PSc p is the permeability-surface area product of the vascular wall multiplied by the concentration of contrast agent in the blood plasma; and PSc e is the permeability-surface area product of the vascular wall multiplied by the concentration of contrast agent in the extracellular-extravascular space.
(https://www.embracestudy.dk), an international study of MRI-guided brachytherapy in locally advanced cervical cancer. All protocols were approved by the local medical ethics research board. Ten patients with advanced-stage cervical tumors (International Federation of Gynecology and Obstetrics: IIA/IIB/IIIB/IVA -1/5/3/1) were scanned before, and 2 to 3 weeks after, the start of RT. This patient population was previously described in Kallehauge et al (19) .
Data were acquired on a 3 Tesla (T) Philips Achieva scanner by means of a three-dimensional (3D), saturation-recovery spoiled gradient-echo sequence [repetition time (TR) ¼ 2. Each DCE-MRI dataset consisted of two dynamic MRI sub-datasets: (i) the AIF dataset obtained from monitoring the external iliac artery and (ii) the tissue response dataset obtained from monitoring the cervix. An AIF for each patient (pre-and post-RT) was obtained by averaging multiple contrast agent concentration versus time curves measured in the external iliac artery. All concentration versus time curves were inspected manually to exclude curves that were affected by partial-volume effects.
Following the work of Fram et al (30) , a T 1 relaxation time-constant map was constructed using the variable flip angle method (flip angles ¼ 5 , 10 , 15 , 20 , and 25 ) by means of a 3D, spoiled gradient-echo sequence before contrast-agent administration, allowing conversion of DCE-MRI signal intensity into contrast-agent concentration, as described in Kallehauge et al (31) . Because a short echo time (TE ¼ 1.4 ms) was used to collect the data, T Ã 2 dephasing was ignored for this conversion. To avoid inflow artefacts in the iliac artery, a literature value of 1660 ms (32) for precontrast blood T 1 was used. Tumor tissue was identified and segmented on T 2 -weighted images by an experienced radiologist. Figure 2 shows four representative single tumor-voxel DCE datasets.
In Silico DCE-MRI Data
In silico DCE-MRI data were generated based upon clinical pretreatment DCE-MRI data from four cervical cancer patients. Both whole-tumor average (mean C t across all voxels) and single-voxel DCE time courses (one tumor voxel from each patient) were examined for these four patients (eight DCE time course datasets in total). The four whole-tumor average DCE datasets provided high contrast-to-noise at the expense of averaging DCE responses from a heterogeneous tissue (cancer). The four single-voxel DCE datasets provided a local DCE response at the expense of reduced contrast-to-noise. These two data-analysis strategies (region-of-interest and voxelwise) are common to literature reports. Together with the measured upstream AIFs for each patient, these eight different DCE datasets, a whole-tumor ROI and a single tumor-voxel from each of four patients, were then each modeled by Bayesian-based algorithms (vide infra) using each of the four tracer kinetic models (eight DCE datasets Â four DCE kinetic models).
For each of the eight DCE datasets, the estimated parameter values obtained for each of the four DCE kinetic models (2CXM, CTUM, ETM, TM; see Supporting Figure S1 , which is available online, for parameter ranges) were then used to generate four noiseless in silico DCE datasets, corresponding to each of the four kinetic models. Summarizing, based on analysis of the clinical data, eight, noiseless, differently parametervalued, in silico, DCE datasets were generated for each of the four DCE kinetic models.
For each of the simulated datasets, the temporal resolution, T s (2.1 s), and total acquisition time, T acq (250 s), were identical to those of the clinical DCE-MRI dataacquisition protocol. Normally distributed (Gaussian) noise (standard deviation from 0 to 0.2 mM in 0.005-mM steps) was then added to each of the simulated noisefree dataset. As such, the CNR, defined as the ratio of the maximum contrast-agent concentration to the noise standard deviation, ranges from infinity (no noise added) to approximately three. For each noise power, 100 different noise representations were simulated. Gaussian noise was used for two reasons. First, Gudbjartsson and Patz (33) have shown that MRI data noise distributions are nearly Gaussian for SNR larger than 2, which is very likely to be true for most DCE-MRI scans. Second, the distribution of baseline signal, i.e., "baseline contrast agent concentration" (essentially pure noise), calculated for all of the cervical tumor voxels, was well fit by a Gaussian model (see Supporting Figure S2 ).
Bayesian-Based Model Selection (and Parameter Estimation)
Bayesian probability theory was used to compute the posterior probabilities for all models on a voxel-by-voxel basis, using Bayes' Theorem (27) ,
where PðMjDIÞ is the posterior probability for the M 'th model, given the data, D, and all of the prior information, I. On the right-hand side of this equation, PðM jIÞ is the prior probability for the M 'th model and PðDjMIÞ is the marginal direct probability for the data, given the model and the prior information. Finally, PðDjIÞ is the direct probability for the data, given the prior information, and serves as a normalization constant. [3] where the normalization constant has been dropped. PðK trans v e jMIÞ is the joint prior probability for K trans and v e , given the model M (in this case, the TM) and the prior information; and PðDjK trans v e MIÞ is the direct probability for the data (the likelihood function), given K trans , v e , the model M, and the prior information. A key feature of Bayesian-based model selection is that it integrates over the joint posterior probability for all of the parameters, thereby taking into account all of the possible parameter-value combinations. The importance/ weight ("penalty") assigned to each parameter derives naturally from that parameter's contribution to the likelihood function of the modeled data (i.e., its posterior probability), which distinguishes the Bayesian approach from other constrained optimization methods.
The posterior probability for the model indicator, given the data and the prior information, PðM jDIÞ, was approximated using a MCMC calculation with simulated annealing (i.e., the MCMC calculation and simulated annealing were used to approximate the complex, analytically intractable, multidimensional integral in Eq. [3] ). Initial values for all of the parameters, including the model indicator, were sampled from the prior probabilities for each parameter and the model indicator. Uniformly distributed prior probabilities, bounded by appropriate physiologic ranges, were assigned to all of the parameters (see Supporting Table S1 ) and to the model indicators (i.e., all four models were assumed to be equally likely).
In simulated annealing, an annealing parameter, b, which varies from 0 to 1, is introduced by raising the direct probability of the data to the b power. When b ¼ 0, the direct probability of the data is zero and the priors are sampled independent of the data. The data are then slowly brought into the simulation as b increases and, when b ¼ 1, the full joint posterior probability for the parameters and model indicators is sampled. In this MCMC calculation, the model is varied by proposing a new model indicator and then simulating (i.e., drawing samples for) the new model parameters. After this new proposed model has reached equilibrium, i.e., the distributions of the drawn model parameter values in MCMC are stationary, the proposed model is either accepted or rejected using the Metropolis-Hastings acceptance criteria (34) . If the proposed model is accepted, the annealing step is complete. However, if the proposed model is rejected, the calculation returns to the original model and new values for the model parameters are proposed. At the completion of the calculation, the posterior probabilities for all the models and their parameters are approximated by the distributions of the Markov chain samples.
All model-selection calculations for in silico and clinical DCE-MRI data were performed using a Bayes DataAnalysis Toolbox (http://bayesiananalysis.wustl.edu) developed by G. Larry Bretthorst. All DCE-MRI contrast agent concentration signal models were written in Fortran and then loaded into the Image Model Selection package within this Toolbox. Computations were carried out on Dell PowerEdge R900 servers (Dell, Inc., Round Rock, TX), vintage 2008. All MCMC calculations were performed with 48 simulations and 50 repetitions; a total of 2400 simulations were run for each dataset (one voxel). For each simulation, a minimum of 50 annealing steps was used. Using a server with 24 CPUs, the average computation time for one patient was approximately 12 h.
Statistical Analysis
All traditional (frequentist) statistical analyses were performed in Matlab (The Mathworks, Inc., Natick, MA). For changes in gross tumor volume, model selection, and parameter estimation on the clinical DCE-MRI data, a paired, two-sided Wilcoxon signed rank test was used to compare the pre-and post-RT time points in a matched manner. Statistical significance was set at P ¼ 0.05.
RESULTS
In silico data were generated based on the clinical cervical cancer DCE-MRI data from four different patients. Figure 3 summarizes the model selection and parameter estimation results for in silico data simulated based on the whole-tumor average DCE-MRI data of patient #1. In Figure 3a , model selection was used to analyze in silico data simulated based on each of the four DCE models. At each noise power, 100 independent simulations (i.e., different noise sets) were performed and the number of "correct" selections, in which model selection chose the model used to simulate the data, was recorded. The number of correct model selections varied as a function of both model complexity and noise power (i.e., CNR). When the added noise standard deviation (SD) < 0.015 mM (i.e., CNR > 36), which is small compared However, as the CNR decreased, simpler data representations were preferred relative to more complex models. For data created based on the 2CXM, the number of correct selections dropped when the noise SD > 0.015 mM. For data created based on the ETM, the number of correct selections dropped when the noise SD > 0.055 mM (i.e., CNR < 10); for data based on the CTUM, the threshold was a noise SD > 0.10 mM (i.e., CNR < 5). By contrast, for the TM, the simplest model, model selection chose the correct model even when the noise SD increased to 0.2 mM (i.e., CNR ¼ 3). For CNR much lower than 3, model selection chose the "no signal" model (data not shown). Figure 3b Figure S3 ) show how the accuracy and uncertainty of estimations of v e , the only common parameter between the simplest model, the TM (Fig. 3c) , and the most complex model, the 2CXM (Fig. 3d) , varied as Gaussian noise was added to each noiseless in silico dataset. While the accuracy of the v e estimation for each model remained stable as CNR decreased, the uncertainties (i.e., error bars) of the estimated v e were much smaller for the TM relative to the more complex 2CXM. FIG. 7. Pharmacokinetic parameters estimated using the optimal DCE-MRI kinetic models for all ten subjects in this study. a-c: Paired scatter plots of median pharmacokinetic parameter estimates, both pretreatment and 2 to 3 weeks following the start of RT, for tumor voxels in which the TM is the optimal model (K trans in Panel a) and those in which the CTUM is the optimal model (F p in Panel b and PS in Panel c). Here, * indicates P < 0.05, and ** indicates P < 0.01, as calculated by a paired, two-sided Wilcoxon signed rank test.
Are Complex DCE-MRI Models Supported by Clinical Data?
trends are the same as shown in Figures 3a and b (qualitatively similar results are also obtained for kinetic parameter values extracted from the perfusion literature, and for a different set of DCE models, see Supporting Figure S4 ). As CNR decreased, the number of correct model selections varied as a function of both CNR and model complexity. Consistently, correct selection of complex models required higher CNR (lower noise power) than simpler models. CTUM and ETM, despite having the same number of model parameters, behaved consistently differently. As CNR decreased, the complex 2CXM was replaced by the simpler CTUM, and, eventually, by the simplest TM. However, for each model, the specific noise power at which the number of correct selections started to decrease depended on the kinetic model's parameter values, which were derived from the original clinical DCE data used to simulate the in silico data. Note that the kinetic model's parameter values affect the MRI contrast agent entering the tissue, which also influence the CNR of the acquired DCE-MRI data.
Bayesian model selection was then applied to the full set of clinical DCE-MRI cervical cancer data acquired from ten patients. Figure 2 illustrates example contrastagent concentration versus time curves from four individual voxels within a single cervical tumor (Patient 1), in which the 2CXM (Fig. 2a) , CTUM (Fig. 2b) , ETM (Fig.  2c) , or TM (Fig. 2d) , respectively, are the Bayesianpreferred tracer kinetic models. While each of the four models was preferred in some individual voxels, Figure  6a shows that the TM and CTUM were overwhelmingly selected as best representing cervical cancer DCE-MRI data acquired both pretreatment and 2 to 3 weeks following the start of RT (see Supporting Figure S5 for optimalmodel maps of example tumor slices). After 2 to 3 weeks of therapy, the percentage of voxels best fit by the TM dropped by 19% (P ¼ 0.16), while the percentage of voxels best fit by the CTUM increased by 14% (P ¼ 0.19).
Based upon a paired, two-sided Wilcoxon signed rank test, neither of these changes is statistically significant. Defining CNR as the ratio of the maximum contrast-agent concentration to the baseline noise standard deviation (calculated before the arrival of the main contrast-agent bolus), Figures 6b and c illustrate the CNR distributions of voxels across 10 subjects (pretreatment in Figure 6b , and 2 to 3 weeks following the start of RT in Figure 6c ), in which either the TM or CTUM were the optimal models. For cervical cancer data collected both pretreatment and 2 to 3 weeks following the start of RT, the median CNRs for data best modeled by the CTUM were larger than for data best modeled by the TM (18.9 versus 14.3, and 21.4 versus 15.0, respectively).
Next, the two dominant models, TM and CTUM, were used to estimate pharmacokinetic parameters for cervical tumor voxels in which each was preferred. Three pharmacokinetic parameters (K trans from the TM, and F p and PS from the CTUM) relating to tissue perfusion and capillary permeability increased 2 to 3 weeks into RT. Figure Figure S6 .
DISCUSSION
The central goal of this study was to test the performance of complex DCE-MRI models in the context of a pool of competing models against: (i) in silico DCE-MRI data simulated based on each of the four models and (ii) clinical DCE-MRI data acquired before and 2 to 3 weeks following the initiation of RT in a cohort (n ¼ 10) of advanced-stage, cervical cancer patients. For the clinical data, parameters were estimated, on a voxel-by-voxel basis, using the selected, optimal kinetic model for each voxel.
The determination of an appropriate kinetic model is essential for extracting quantitative tissue perfusion and vascular permeability parameters from DCE-MRI data. Complex models (i.e., those with more parameters) will always provide better fits in terms of residuals alone (e.g., Chi-square). However, the inclusion of additional parameters may not be well supported by the acquired DCE-MRI data, and may, consequently, increase the uncertainty (variance) in the estimation of the parameters within the model.
Our simulation study shows that complex DCE-MRI models are more sensitive to CNR than simpler models with respect to both model selection (Figs. 3a,b , [4 and 5] ) and parameter estimation (Figs. 3c,d ; Sup. Fig. S5 ). As noise standard deviation increases (i.e., CNR decreases), Bayesian model selection chooses simpler data representations (Figs. 3b, 5) , a statistically rigorous manifestation of Occam's razor. Similarly, as CNR decreases, uncertainties in parameter estimates for highly parameterized models increase much more rapidly than for simpler models (Figs. 3c,d) and Bayesian model selection chooses simpler models. For two models having the same complexity (i.e., the same number of model parameter), the CTUM is more robust than the ETM (Figs. 3a, 4) for the data examined herein.
Although each of the four models is preferred in some individual tumor voxels (Fig. 2) , the TM and CTUM are the two dominant models for the acquired cervical cancer DCE-MRI data (Fig. 6a) . The 2CXM and ETM were seldom selected, a finding that agrees well with our in silico results. As shown in Figures 3b and Figure 5 , as CNR decreases, the general 2CXM reduces to the CTUM and eventually to the TM. Among the two preferred kinetic models, selection of the three-parameter CTUM generally requires higher CNR than the two-parameter TM (Figs. 6b,c) . However, choice of the optimal (most probable) model also depends on other factors beyond CNR, including kinetic/compartmental constraints imposed by physiological conditions, which explains the overlap of CNR distributions between the TM and CTUM in Figures 6b and c. For example, when the total acquisition time course is short or the extracellular extravascular space (EES) is large, the forward contrast-agent flux from plasma to EES is much larger than the contrastagent backflux from EES to plasma. Under such conditions, the CTUM, which ignores the backflux, is the physiologically more appropriate model (16) and, thus, better represents the acquired dynamic curves.
In heterogeneous tissue such as cancer, DCE model selection poses the "mixed tissue conundrum." This is illustrated in the current case where different tumors, the same tumors at different times (e.g., before and after treatment), different tumor regions, and different tumor voxels support different DCE models, making it difficult to compare modeling results (e.g., intermodal comparison of estimated model-specific parameter values). However, in highly heterogeneous tissues such as cancer, this is not an unexpected result. Different tumors, different tumor regions, and different tumor voxels possess different physiologic and microstructural characteristics. Indeed, to a large extent, it is the competing models themselves that provide the desired tissue discrimination/characterization. In this light, transformation from one model to another in the face of therapy or other physiologic challenge may provide an important metric for patient care.
Choosing one commonly used "simpler" pharmacokinetic tracer model (without model selection justification) for data analysis would not avoid but, instead, hide the underlying mixed tissue conundrum by losing information and biasing parameter estimates. Whether DCE voxelwise data of sufficient quality can be obtained such that a "more complex" model would be the most probable for all (or the substantial majority of) voxels in a truly heterogeneous tissue such as cancer is an interesting but open question. However, data from voxels that are well-fit by a simple model are likely to be inadequate to support a more complex model vis-a-vis Occam's razor.
In addition to CNR investigated in this study, both temporal resolution and acquisition time window will also affect the ability of the kinetic models to fit the data, which will consequently affect model selection results. An extensive examination of how each of these factors affects model selection results is beyond the scope of this study. Therefore, it is impossible to draw universal conclusions regarding whether a given DCE model can be supported or not at a specific noise power (or temporal resolution or acquisition time). For each individual DCE-MRI dataset, data-driven model selection must be performed for the identification of voxel-specific optimal (most probable) models.
Biophysical properties not investigated in this study, but which may also affect the signal response in clinical DCE-MRI studies, include T Ã 2 dephasing, water exchange, inter-voxel convection (contrast agent flux from highly leaky voxel to less leaky voxels), and AIF accuracy (bolus dispersion and partial volume effects). All of these effects may influence the acquired DCE signal and, thus, affect the tracer kinetic modeling and model selection. Models that fully account for these effects, which were not included in this study, must incorporate more free parameters and thus have higher model complexity. Even though such models are physiologically more correct and more general in terms of applicability, it is likely that data quality would have to be exceptionally high to justify their use versus less complex models. In this context, for any given DCE-MRI dataset, data-driven model selection is a necessary prerequisite.
It is worth stressing here that there is no substitute for a well-considered data acquisition protocol, i.e., high quality data. Without such a protocol, even the most sophisticated postacquisition analysis is left with effects that cannot be estimated in a reasonably small set of model parameters, but which will influence parameter estimates. Importantly, DCE signal effects related to T Ã 2 dephasing, water exchange, and AIF bolus dispersion and partial voluming can be minimized by optimizing the data acquisition protocol. For instance, T Ã 2 dephasing can be computed by means of a dual-echo sequence (35) , and the water exchange effect can be suppressed by a careful selection of flip angle (36) . In addition, the AIF accuracy can be improved by the selection of a reference region (37) .
We note here that the estimated values for parameters shared among these DCE models are different from model to model, and that some of the computed values in some models are apparently nonphysical (e.g., large 2CXM and CTUM v p ). The model selection and parameter estimation algorithms described herein are not the source of such biases. Our in silico simulation study (Fig. 3) , in which parameter values were estimated accurately, but with decreasing precision, as contrast-to-noise decreased, provides prima facie evidence that parametric biases in our study are not due to the modeling algorithms. Rather, the models are unavoidably wrong (i.e., are simplifications of a very complex tissue physiology), the data collection is unavoidably constrained/compromised by scanner capabilities, and the clinically achievable contrast-to-noise is unavoidably modest. Thus, while the estimation procedure is unbiased, the models and the data are biased. Therefore, that some parameter estimates seem physiologically implausible is not surprising and is not limited to this study but occurs throughout the literature. For example, while the ETM (also known as the Extended Patlak Model) usually produces v p less than 0.1, studies (19, 21, (38) (39) (40) (41) using the newer 2CXM produces substantially higher v p (up to 0.44). Whether the parameters so obtained are of clinical value in cancer detection and management is beyond the scope of this investigation. Nevertheless, the continued presence of such studies in the peer-reviewed literature suggests that the DCE-MR community believes such studies do have value, a manifestation of Box's dictum (42) .
The use of quantitative pharmacokinetic parameters to evaluate the therapeutic response of tumors has been demonstrated in several studies (43) (44) (45) (46) . Our data showed that F p , PS, and K trans , which is a mixture of F p and PS (16), increased during the early stages (2 to 3 weeks) of RT (Fig. 7) . These changes are consistent with DCE-MRI results from previous studies (44,45) on preand postradiotherapy cervical cancer. We caution that changes observed herein are only for voxels defined as tumor based on T 2 -weighted images. Furthermore, it has been shown that possible underlying biological processes that are secondary to the radiotherapy (47) , such as inflammation, may confound quantitative DCE-MRI measures of tumor perfusion and permeability, especially at early stages of treatment. Monitoring long-term patient outcomes, including both MR and clinical tumor indices, is necessary before making inferences regarding therapeutic response.
In conclusion, we have applied Bayesian-based algorithms to DCE-MRI tracer kinetic model selection and parameter estimation. Both DCE-MRI model selection and parameter estimation are sensitive to model complexity and data quality. Highly parameterized, complex models require higher data quality for accurate and stable model parameter estimation. In the absence of performing a model-selection calculation, these complex models should be used cautiously. The two-parameter TM and the three-parameter CTUM were found to be the two dominant models for the clinical DCE-MRI cervical cancer data examined herein. Beyond other physiological factors, the three-parameter CTUM required higher CNR than the two-parameter TM. Significant changes in tumor perfusion and permeability (K trans , F p , and PS) were found during the early stages of RT. Correlating pretreatment pharmacokinetic parameters with long-term treatment outcomes, such as local control and diseasespecific survival, will be the subject of future work.
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Additional Supporting Information may be found in the online version of this article. Table S1 . Prior ranges a for all the parameters within the response functions. Fig. S3 . a: For data simulated based upon 2CXM (as shown in Figure 3 ), the estimates of v e , modeled as either 2CXM (red) or TM (black), as a function of added noise. b: For data simulated based upon ETM (as shown in Figure 3 ), the estimates of K trans , modeled as either ETM (red) or TM (black), as a function of added noise. The differences between the traces in each panel, reflecting biases in parameter estimates, result from physiologic approximations and constraints inherent in the simpler TM model (see Sourbron and Buckley for details) 16 . ; v e : 0.32) extracted from the perfusion literature 48-51, and a population AIF, as described by Parker et al 52. In both model selection and parameter estimation, a new set of DCE-MRI models [i.e., the four-parameter 2CXM; the three-parameter ETM; the two-parameter Patlak model; and the one-parameter SSM 16] were used. In a, the number of times each model was selected as a function of noise SD, given 100 different noise representations at each fixed noise SD, ranging from 0 to 0.2 mM (corresponding to CNR % 2), is plotted. As a reference, the median CNR for the cervical cancer DCE-MRI data investigated in this study is approximately 19. In b, the mean v p estimated for each model, considering the 100 different noise representations at each fixed noise SD, is plotted. Note that at low CNR (e.g., CNR < 5 for the 2CXM), the mean of the 100 v p estimates for each of three of the models increased. This is because results of the MCMC sampling are increasingly weighted by the priors as the data become increasingly uninformative. In the case of v p , a uniform prior over the range 0-1 was used. As the "ground truth" value of v p 5 0.05, it lies at the low end of the prior range. As data become increasingly uninformative and the v p prior more influential in the MCMC sampling, the estimated value of v p trends toward the middle of the uniform prior's range. 
